Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘epizyme’

Epizyme to Participate in Upcoming September Conferences

Posted by fidest press agency su sabato, 31 agosto 2019

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following September investor conferences:
Citi 14th Annual Biotech Conference’s “Focusing the Laser on Precision Oncology – Part 2” Company Panel on Thursday, Sept. 5, 2019 at 9:30 a.m. ET in Boston; and,
Morgan Stanley 17th Annual Global Healthcare Conference (fireside chat) on Monday, Sept. 9, 2019 at 3:40 p.m. ET in New York City.
Live webcasts will be available in the investor section of the company’s website at http://www.epizyme.com. The webcasts will be archived for 60 days following the presentations.
Epizyme, Inc. is a late-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, an oral, first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme’s science seeks to match targeted medicines with the patients who need them. For more information, visit http://www.epizyme.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Epizyme to Participate in Upcoming Investor Conferences

Posted by fidest press agency su sabato, 1 settembre 2018

New York. Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor conferences: Citi’s 13th Annual Biotech Conference in Boston – Panel discussion at 3:15 p.m. ET on Wednesday, September 5, 2018.
Morgan Stanley’s 16th Annual Global Healthcare Conference in New York City – Fireside chat at 2:50 p.m. ET on Wednesday, September 12, 2018
Leerink Partners 2018 Rare Disease & Oncology Roundtable in New York City – Fireside chat at 10:00 a.m. ET on Wednesday, October 3, 2018
To access a live webcast of these presentations, please visit the Events & Presentations page within the Investor section of the company’s website at http://www.epizyme.com. A replay of each webcast will be available on the Epizyme website for 60 days following the event.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme’s science seeks to match targeted medicines with the patients who need them. For more information, visit http://www.epizyme.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »